Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XENITH: Rivaroxaban for PE Managed With CDT
NCT02506985Phase 4Terminated
- Start
- Jul 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
01
Overview
A Phase 4 trial of rivaroxaban in pulmonary embolism (PE). Started Jul 2015; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT02506985.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506985.